Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Dow Agrosciences LLC

Sekisui Chemical Co., Ltd.

Evonik Roehm Gmbh

University of Cape Town

Rheinisch-westfaelische Technische Hochschule Aachen

Justus-liebig-universitaet Giessen

Rheinisch-westfalische Technische Hochschule Aachen

Bayer Intellectual Property Gmbh

Evonik Operations Gmbh

Rwth Aachen

Evotec Technologies Gmbh

Jüstus-liebig-universität Giessen

Rainer Fischer

Stefan Barth

Andreas Reimann

Stefan Schillberg

Markus Sack

Holger Spiegel

Andreas Vilcinskas

Torsten Klockenbring

Gueven Edgue

Rolf Fendel

Veronique Beiss

Alexander Boes

Stephanie Kapelski

Yu-Cai Liao

Dominika Maskus

Dirk Pruefer

Michael Stöcker

Kenneth Edwin Narva

Akihiro Uenishi

Norbert Windhab

Stefan Jennewein

Sarah E Worden

Mariola Fotin-Mleczek

Koichiro Iwasa

Meghan Frey

Krishna M Madduri

Masahiro Furutani

Premchand Gandra

Elane Fishilevich

Murugesan Rangasamy

Simon Vogel

Janna Mai Armstrong

Audrey Jane Etter

Hans-Juergen Hamann

Wendy Lo

Eileen Knorr

Ricarda Finnern

Mehmet Kemal Tur

Fatima Ferreira

Matthias Buntru

Christian Schulze Gronover

Sabine Zimmermann

Raluca Ostafe

Ahmad Fawzi Hussain

Stefan Hofmann

Dirk Prüfer

Greta Noelke

Radoslav Mladenov

Elke Luger

Lea Christin Schenke

Dieter Peschen

J&ouml;rg N&auml;hring

Sabine Zimmerman

Michael Monecke

Stefano Di Fiore

Fritz Kreutzaler

Mirna Barsoum

Janina Kirchhoff

Bernhard Stockmeyer

Andreas Schiermeyer

Helga Schinkel

Boje Mueller

Mark Salzig

Simone Dorfmüller

Roland Brock

Neil Emans

Ulrich Commandeur

Torsten Will

Lena Harig

Christina Dickmeis

Hansjoerg Hufnagel

Radivoje Prodanovic

Christoph Stein

Gernot Achatz

Michael Huhn

Kurt Herrenknecht

Lea Christin Hein

Will Torsten

Hansjorg Hufnagel

Michael Stoecker

Greta NÖLKE

Boje MÜLLER

Edgü GÜVEN

Carmen Vaquero-Martin

Stefan Vogel

Carlo Jochems

Stephan Hurling

Theo Thepen

Mei Yun Zhang

The technology provided herein generally relates to novel specific photoimmuno-theranostics for the use in detection and elimination of skin cancer cells. The technology also relates to novel methods which generate homogeneous and specific photoimmuno-theranostics reagents in a simple, controlled and efficient way. This method combines molecular optical imaging, photodynamic therapy and immunotherapy using SNAP-tag technology.

Specific photoimmuno-theranostics for detection and elimination of skin cancer cells

The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.

Pest control methods

The present invention is directed to nucleic acid sequences coding for a protein which, (1) under a respective promoter, is able to suppress or repress or delay flowering of a plant, and (2) includes the motive 'NAPDIIDS' (SEQ ID NO: 10) or, in preferred cases, 'VNAPDIIDS' SEQ ID NO: 67), with the exception of the nucleic acid of the gene StSP5G or a part thereof. Preferably, the nucleic acid sequence belongs phylogenetically to the FT-clade of the PEBP gene family, wherein the motive &#x201c;(V)NAPDIIDS&#x201d; (SEQ ID NO: 68) is in place of the &#x201c;(V)YAPGW&#x201d; motive (SEQ ID NO: 69) of the flowering promoting proteins AtFT and BvFT2. The invention is further directed to peptides or proteins, obtainable by expression of the nucleic acid of any of the preceding claims, vectors, comprising a nucleic acid sequence as defined above, and to plants, parts of plants, or seed of plants, the plants comprising such a nucleic acid sequence.

Nucleic acid sequences and peptides/proteins of the FT family providing flower repressing properties in tobacco and transgenic plants transformed therewith

Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferablyexotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.

Anti-CD89 cytotoxic complex

This disclosure concerns the systems, methods, and kits for the in vitro synthesis of biological macromolecules in a reaction utilizing cell lysates containing plastids, mitochondria and/or chloroplasts, wherein creatine phosphate and creatine kinase are not added to the reaction to provide artificial energy regeneration.

Eukaryotic cell-free protein expression system that does not require an artificial energy regeneration system

The technology provided herein relates to novel human antibodies againstparasites, in particular against the malaria parasite. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. toschizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Anti-plasmodium parasite antibodies

The technology provided herein generally relates relates to genetically modified higher plants, for example C3 and C4 plants, and subsequent generations thereof, comprising stable and/or transient expression of at least one gene-product (e.g. mRNA or protein) of the 'CO2 concentrating mechanism' (CCM), wherein the expression takes place in the intermembrane space and/or one or more subcellular compartments of the chloroplasts of the higher plant, and wherein this expression increases one or more of the characteristics selected from the group of photosynthetic rate, photosynthetic carbon fixation, chlorophyll level and/or biomass of the genetically modified higher plant (T0) and/or of the T1 and/or T2 generation or any subsequent plant generation of said genetically modified higher plant.

Genetically modified higher plants with increased photosynthesis and/or biomass production, methods and uses thereof

This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.

FSH nucleic acid molecules to control insect pests

The invention provides a method for the generation of a monoclonal plant cell line from a heterologous population of plant cells, comprising the following steps: (a) provision of a heterologous population of plant cells; (b) preparation of protoplasts from said heterologous population of plant cells; (c) separation of single protoplasts by subjecting the preparation of protoplasts to flow cytometric sorting; (d) regeneration of a separated single transformed protoplast until the formation of a microcolony by co-cultivation in the presence of feeder cell material; (e) removal of the microcolony from the feeder cell material and cultivation of the microcolony until the formation of a monoclonal plant cell line.

Method for the generation of a monoclonal plant cell line

The invention relates to artificial forisome bodies including a fusion protein of at least one SEO-F protein or an at least 50-amino acid portion thereof, and at least one additional protein or peptide, with the exception of GFP and the Venus protein, wherein in an embodiment the forisome body further includes an unfused SEO-F protein or a form of the protein having C-terminal deletions of up to 45 amino acids and/or N-terminal deletions of up to 13 amino acids, wherein the unfused SEO-F protein is selected from proteins having the property of being capable of forming homomeric forisome bodies in the absence of additional SEO-F proteins.

Artificial forisome body with SEO-F fusion proteins, plant or yeast cells comprising vectors which code for these proteins, as well as vectors which code for SEO-F fusion proteins

The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against() comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Anti-parasitic complexes

A composition comprising as components a polypeptide IMPI&#x3b1; (including wild type) and/or a polypeptide IMPI&#x3b1;-fusion and at least one antibiotic compound, in particular an aminoglycoside antibiotic, and/or at least one bactericidal compound, wherein the polypeptides, the at least one antibiotic and the at least one bactericidal compound is present in the composition in concentrations which exhibit in combination a synergistic effect against resistant bacteria.

Use of metalloproteinase inhibitors against bacterial infections

The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several differentantigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Three-component-multistage malaria vaccine

The present invention relates to kits comprising plus-sense single stranded RNA viral vectors, as well as mixtures of these vectors and uses thereof, and methods for producing in a plant, or plant tissue, or plant cell simultaneously two or more polypeptides using the kits and vectors.

Kits comprising plus-sense single stranded RNA viral vectors and methods for producing polypeptides using the kits

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several differentantigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Multi-component-multistage malaria vaccines

Growing community of inventors

Aachen, Germany

Rainer Fischer